PERSPECTIVE THERAPEUTICS INC

CATXNYSE AMERICAN

🏆 #2839 by market capEarnings Nov 17US Equity

$3.15▼ $0.03 (−1.10%)

Live

1h▼ 2.0%

24h▼ 1.1%

7d▲ 7.0%

14d▲ 9.2%

30d▲ 1.5%

1y▼ 20.6%

🏦Market Cap

$359M

Small Cap

📈Revenue Growth (YoY)

-100.0%

Declining

📊Gross Margin

-608.7%

Thin

💵FCF Margin

-48090.1%

Thin

⚖️P/S Ratio

1423.3x

Expensive

Otter Score

Weak

Trading Snapshot

Day Range: $3.13 – $3.16
52-Week Range: $1.96 – $6.16
Volume: $2.61B
Avg Volume: $2.68B
Shares Outstanding: 114.0M
Next Earnings: Sep 9, 2026

Fundamentals Snapshot

Annual Revenue: $252,000
Last Q Revenue: $67,896
P/E Ratio: -2.4
P/S Ratio: 1423.3x
EPS (TTM): $-1.04
Dividend Yield: 0.00%

Why Investors Own CATX

✓High-growth profile — revenue up +1.1% YoY with expanding US Equity exposure.
✓Healthy economics — 66% gross margin and 10% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$252,000▲ +1.8% YoY

Gross Margin (TTM)

66.1%▲ +2.5% YoY

Operating Income (TTM)

$74,088▲ +1.8% YoY

Free Cash Flow (TTM)

$24,444▲ +1.8% YoY

About PERSPECTIVE THERAPEUTICS INC

Perspective Therapeutics, Inc., including its various operations, specializes in the comprehensive lifecycle – from development and manufacturing to sales and marketing – of radiopharmaceutical products and medical devices. These advanced solutions are designed to treat cancer and other serious malignant conditions, serving markets both within the United States and globally. A flagship product offered by the company is its CS-1 Cesium-131 brachytherapy seeds. This treatment is specifically utilized for a broad range of cancers, such as those impacting the prostate, brain, lung, head and neck regions, gynecological system, pelvic/abdominal areas, and colorectal tissues. The company distributes its products to medical facilities and physician practices equipped with surgical capabilities. The entity originally operated under the name Isoray, Inc., before officially adopting the name Perspective Therapeutics, Inc. in February 2022. Founded in 1998, the company maintains its corporate headquarters in Richland, Washington.

🦦